96 Tests PN: B111446

Components:

45x Ab-conjugated beads (S4P7 - human Survivin Ab-bead). PN: B111446A. One vial containing 100 µL of anti-human Survivin conjugated to AimPlex Bead S4P7.

25x Biotin-detection Ab (human Survivin Biotin-dAb). PN: B111446B. One vial containing 100 µL of biotinylated anti-human Survivin.

Lyophilized Standard Mix-Human Group 4 Panel B, 10-Plex. PN: HG40010. One vial containing lyophilized recombinant human GASP-1, IFNβ, ANGPT-1, Insulin, Leptin, MIF, Resistin, Survivin, TGFα, and TPO. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

Application: Optimal antibody pair and antigen standard for assaying human Survivin.  Can be multiplexed with other analytes in Human Group 4.  To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 10 pg/mL

  • Quantitation range:

  • LLOQ: < 20 pg/mL

  • ULOQ: > 5,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Cross-reactivity of analytes in Human Group 4: Negligible

  • Sample volume: 15 µL/test

Description:

Survivin (Accession O15392) is a member of the Inhibitor of Apoptosis family. It is synthesized in T cells, neutrophils, and vascular endothelial cells. Survivin plays a role in cytokinesis and mitosis, as it can localize the mitotic spindle by interacting with tubulin. It is overly expressed in most human tumors, though absent in fully differentiated cells. Its increased presence is associated with chemotherapy resistance, decreased chance in patient survival, and increased tumor recurrence. All of which make Survivin a potential target for cancer therapies and as a biomarker for certain cancers.

References:

  1. Altieri DC. Validating surviving as a cancer therapeutic target. Nature Rev Cancer. 2003; 3(1): 46-54. Doi: 10.1038/nrc968.

  2. Duffy MJ, O’Donovan N, Brennan DJ, Gallagher WM, Ryan BM. Survivin: A promising tumor biomarker. Cancer Letters. 2007; 249(1): 49-60. Doi: 10.1016/j.canlet.2006.12.020.

  3. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Therap. 2006; 5(5). Doi: 10.1158/1535-7163.MCT-05-0375.